神經保護市場:現狀分析與預測(2022-2030年)

由於神經系統疾病患病率不斷上升，神經保護市場預計將以6%左右的速度穩定增長。由於衰老、遺傳傾向和生活方式等因素，阿爾茨海默病、帕金森病和多發性硬化症等神經系統疾病的發病率正在增加。

根據產品類型，市場分為自由基清除劑（抗氧化劑）、細胞凋亡抑製劑、抗炎劑、谷氨酸拮抗劑（抗刺激毒物）等。由於人口老齡化和阿爾茨海默氏症和帕金森氏症等神經退行性疾??病患病率的上升，自由基清除劑（抗氧化劑）類別在預測期內將表現出較高的複合年增長率，進一步推動該細分市場的增長。

根據應用，它分為神經退行性疾??病、阿爾茨海默病、帕金森病、多發性硬化症等。其中，神經退行性疾??病將在2021年佔據很大的市場佔有率。這主要是由於神經退行性疾??病的患病率不斷增加，人們越來越意識到維持大腦健康的重要性，以及對有效治療的需求推動了神經保護市場的增長。例如，根據國際癌症研究機構的數據，全球大多數研究表明每年每 10 萬人中有 10 至 15 例癌症發病。65歲以上人群的患病率可達2%。調查對象被各終端用戶，醫院·專門診所，研究機關·學術中心，看護設施，其他分類。在預測期間內，一般認為醫院·專門診所的類別神經保護的招聘增加。這為了主要，受到比神經疾病的正確的診斷因為是希望住院的患者多的事，神經疾病的盛行率的增加，個人化醫療的需求高漲等，促進神經科學市場上醫療保健供應商領域的成長。

按最終用戶劃分，調查對象分為醫院/專科診所、研究機構/學術中心、療養院等。在預測期內，醫院和專科診所類別的神經保護採用預計將會增加。這主要是由於越來越多的患者尋求住院接受更準確的神經系統疾病診斷、神經系統疾病的患病率不斷增加以及個性化醫療的需求不斷增長，從而推動了醫療服務提供商領域的增長。

為了更好地了解神經保護行業的市場採用情況，市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、意大利、歐洲其他地區）、亞太地區（中國、日本、印度、亞太地區其他地區）、世界其他地區根據其在世界其他地區的存在情況進行分析。北美在預測期內預計將以顯著的複合年增長率增長，因為它擁有大量老年人口並構成美國社會的很大一部分。根據社區生活管理局的數據，2019 年美國老年人數量自 2009 年以來增加了 1440 萬（即 36%）。隨著年齡的增長，神經系統疾病的風險也隨之增加，這將是神經保護市場增長以應對不斷增加的病例的關鍵因素。此外，該地區和美國等主要經濟體先進技術的存在也有助於北美神經保護行業的重要市場佔有率。

目錄

第1章 市場簡介

• 市場定義
• 主要目的
• 相關利益者
• 限制事項

第2章 調查手法或前提

• 調查流程
• 調查手法
• 受訪者簡介

第3章 市場摘要

第4章 摘要整理

第5章 COVID-19對神經保護市場帶來的影響

第6章 神經保護市場收益，2020-2030年

第7章 市場洞察:各產品類型

• 自由基理解劑(抗氧化劑)
• 細胞凋亡抑制劑
• 抗發炎劑
• 麩胺酸拮抗劑(抗興奮毒性劑)
• 其他

第8章 市場洞察:各用途

• 神經退化性疾病
• 阿茲海默症
• 帕金森氏症
• 多發性硬化症
• 其他

第9章 市場洞察:各終端用戶

• 醫院和專門診所
• 調查機關和學術中心
• 看護設施
• 其他

第10章 市場洞察:各地區

• 北美
  • 美國
  • 加拿大
  • 其他北美地區
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 全球其他地區

第11章 神經保護市場動態

• 推動市場要素
• 市場課題
• 影響分析

第12章 神經保護市場機會

第13章 神經保護市場趨勢

第14章 需求面和供給面的分析

• 需求面分析
• 供給面分析

第15章 價值鏈分析

第16章 價格分析

第17章 策略性洞察能力

第18章 競爭模式

• 競爭情形
  • 波特的五力分析

第19章 企業簡介

• AbbVie Inc.
• DAIICHI SANKYO COMPANY
• Astrocyte Pharmaceuticals
• AstraZeneca
• Biogen
• Novartis AG
• Lilly
• F. Hoffmann-La Roche Ltd
• Teva Pharmaceutical Industries Ltd.
• Merck KGaA

第20章 免責聲明

Neuroprotection refers to the process of protecting the nervous system from damage or degeneration. The nervous system is a complex network of cells and tissues that controls the body's functions, including movement, sensation, and cognition. Neuroprotection can be achieved through various means, including the use of drugs, therapies, and lifestyle modifications. For example, drugs that target specific proteins or enzymes involved in the process of neurodegeneration can be used to protect the nervous system. Therapies such as physical therapy, occupational therapy, and speech therapy can also be used to protect the nervous system by promoting nerve function and preventing further damage.

The neuroprotection market is expected to grow at a steady rate of around 6% owing to the Increasing prevalence of neurological disorders. The incidence of neurological disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis is increasing due to factors such as an aging population, genetic predisposition, and lifestyle factors. For instance, as per WHO, more than 55 million people were diagnosed with dementia in 2021, and there are nearly 10 million new cases every year. Also, in 2019, globally, 50 million people were diagnosed with epilepsy.

Based on product type, the market is segmented into free radical trapping agents (antioxidants); apoptosis inhibitors; anti-inflammatory agents; glutamate antagonists (anti-excitotoxic agents); and others. The free radical trapping agents (antioxidants) category to witness higher CAGR during the forecast period owing to the aging population and the rising incidence of neurodegenerative diseases such as Alzheimer's and Parkinson's are driving the demand for neuroprotection treatments which will further boost the growth of this segment.

On the basis of application, the market is categorized into neurodegenerative disorders, alzheimer's disease, parkinson's disease, multiple sclerosis, and other. Among these, the neurodegenerative disorders held a significant share in the market in 2021. This is mainly due to the increasing prevalence of neurodegenerative disorders, the growing awareness of the importance of maintaining brain health, and the need for effective treatments are driving the growth of the neuroprotection market. For instance, as per International Agency for Research on Cancer, annual incidence rates of 10-15 per 100 000 have been noted in most surveys worldwide. Prevalence may reach 2% in persons aged 65 years and older

Based on end-user, the neuroprotection market has been classified into hospitals & specialty clinics, research institutes & academic centers, long-term care facilities, and others. The hospitals & specialty clinics category is to witness higher adoption of neuroprotection during the forecast period. This is mainly due to the high preference of patients for hospitalization to have a more accurate diagnosis of their neurological diseases, increasing prevalence of neurological disorders, coupled with the rising demand for personalized medicine, is driving the growth of the healthcare provider segment in the neuroscience market.

For a better understanding of the market adoption of the neuroprotection industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. owing to the North America is home to a large geriatric population and consists of a significant portion of American society. As per the administration for community living, the number of older Americans has increased by 14.4 million (or 36%) since 2009 in 2019. With the rising age, the risk of neurological disorders also increases which becomes an important factor for the growth of the neuroprotection market to deal with the increasing cases. Furthermore, the presence of advanced technology in the region and the major economies such as the U.S. is also a responsible factor for the large market share of neuroprotection industry in North America.

Some of the major players operating in the market include: AbbVie Inc.; DAIICHI SANKYO COMPANY; Astrocyte Pharmaceuticals; AstraZeneca; Biogen; Novartis AG; Lilly; F. Hoffmann-La Roche Ltd; Teva Pharmaceutical Industries Ltd.; and Merck KGaA.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Neuroprotection Market
• 2.2. Research Methodology of the Neuroprotection Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE NEUROPROTECTION MARKET

6 NEUROPROTECTION MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY PRODUCT TYPE

• 7.1. Free Radical Trapping Agents (Antioxidants)
• 7.2. Apoptosis Inhibitors
• 7.3. Anti-inflammatory Agents
• 7.4. Glutamate Antagonists (Anti-Excitotoxic Agents)
• 7.5. Others

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Neurodegenerative Disorders
• 8.2. Alzheimer's Disease
• 8.3. Parkinson's Disease
• 8.4. Multiple Sclerosis
• 8.5. Other

9 MARKET INSIGHTS BY END-USER

• 9.1. Hospitals & Specialty Clinics
• 9.2. Research Institutes & Academic Centers
• 9.3. Long-Term Care Facilities
• 9.4. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 NEUROPROTECTION MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 NEUROPROTECTION MARKET OPPORTUNITIES

13 NEUROPROTECTION MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INSIGHTS

18 COMPETITIVE SCENARIO

• 18.1. Competitive Landscape
  • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

• 19.1. AbbVie Inc.
• 19.2. DAIICHI SANKYO COMPANY
• 19.3. Astrocyte Pharmaceuticals
• 19.4. AstraZeneca
• 19.5. Biogen
• 19.6. Novartis AG
• 19.7. Lilly
• 19.8. F. Hoffmann-La Roche Ltd
• 19.9. Teva Pharmaceutical Industries Ltd.
• 19.10. Merck KGaA

20 DISCLAIMER